Illumina gained the FDA's OK for a number of next-generation gene sequencing diagnostic devices--four in all--marking another advance for technology increasingly eyed for everyday use in regular medical care.
Natera, Illumina's Verinata Health and Ariosa Diagnostics have scored major deals to provide diagnostic testing to California women through the state's prenatal screening program.
Natera, Illumina's ($ILMN) Verinata Health and Ariosa Diagnostics have scored major deals to provide diagnostic testing to California women through the state's prenatal screening program, a coup opening the door to wider patient access in the nation's biggest state.
NextBio was set up to solve a problem partly created by Illumina's success in next-generation sequencing--how to make Big Data accessible and useful to researchers. Now, Illumina is to offer its own solution by acquiring NextBio and combining it with its BaseSpace cloud computing environment.
Over the past 12 months spending cuts at National Institutes of Health have raised doubts about its ability to continue increasing investment in next-generation sequencing at the rate seen in recent years. Yet this week brought two pieces of news that suggest NIH is backing more and more NGS projects.
Illumina's ($ILMN) stock soared more than 10% this week in anticipation of stellar revenue results for the 2013 third quarter, hitting numbers after the market's close Oct. 22 that reflect optimism over healthy gains and new full-year guidance revised higher for the second time in three months.
Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...
Illumina charted another quarter of banner revenue growth and, free from the patent suit loss that tanked its Q1 profits, the gene sequencing leader is counting on its expanded weight in the diagnostics world to deliver a 20% sales boost in 2013.
Illumina has partnered with Hamilton Robotics to develop automated sample preparation for the company's next-generation sequencing platforms.
Illumina put up another stellar revenue quarter, pulling in $331 million, a 21% jump over last year. But last month's lost patent suit to Syntrix Biosystems tacked on a $106.9 million charge, leaving the sequencing heavyweight with a $23 million net loss on the quarter.